endothelin receptors การใช้

• Such regulatory genes include endothelin receptor type B ( EDNRB ).
• BQ-123 is a selective ET A endothelin receptor antagonist.
• Endothelin receptor activation mediates strong pulmonary vasoconstriction and positive inotropic effect on the heart.
• As such, endothelin receptor antagonists such as Ambrisentan are known to be teratogenic.
• It is an endothelin receptor antagonist selective for subtype A ( ET A ).
• It has potent activity as an endothelin receptor antagonist and anti-osteoporosis agent.
• It is an endothelin receptor antagonist.
• As such, it is used as a biochemical tool in the study of endothelin receptor function.
• The subfornical organ also contains endothelin receptors mediating vasoconstriction and high rates of glucose metabolism mediated by calcium channels.
• The multigenic disorder, Hirschsprung disease type 2, is due to mutation in endothelin receptor type B gene.
• Endothelin receptor type B is a G protein-coupled receptor which activates a phosphatidylinositol-calcium second messenger system.
• A mutation in the middle of the endothelin receptor type B ( EDNRB ) gene causes lethal white syndrome when homozygous.
• The preproprotein is processed to a short mature form which functions as a ligand for the endothelin receptors that initiate intracellular signaling events.
• "' Bosentan "'is a dual endothelin receptor antagonist used in the treatment of pulmonary artery hypertension ( PAH ).
• In addition to this, endothelin receptors are also known to play a role in neural crest cell migration, growth, and differentiation.
• Additionally, Myogen was developing ( in Phase 3 studies ) darusentan, also an endothelin receptor antagonist, for the potential treatment of resistant hypertension.
• Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor ( ET A ).
• Ambrisentan, which relaxes those muscles, is an endothelin receptor antagonist, and is selective for the type A endothelin receptor ( ET A ).
• Targeting this axis with orally available endothelin receptor antagonists may prove efficacious in mimicking the inhibitory role of RhoGDI2 by preventing macrophage infiltration into the micrometastatic niche.
• Experimental therapies under investigation include endothelin receptor antagonsits, tyrosine kinase inhibitors, beta-glycan peptides, halofuginone, basiliximab, alemtuzumab, abatacept and haematopoietic stem cell transplantation.